Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031954 | Oral cavity | OSCC | positive regulation of protein autophosphorylation | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:1903421 | Oral cavity | OSCC | regulation of synaptic vesicle recycling | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:00181079 | Oral cavity | OSCC | peptidyl-threonine phosphorylation | 60/7305 | 116/18723 | 3.59e-03 | 1.50e-02 | 60 |
GO:00182109 | Oral cavity | OSCC | peptidyl-threonine modification | 64/7305 | 125/18723 | 3.68e-03 | 1.52e-02 | 64 |
GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
GO:00324652 | Oral cavity | OSCC | regulation of cytokinesis | 49/7305 | 92/18723 | 3.81e-03 | 1.57e-02 | 49 |
GO:004338816 | Oral cavity | OSCC | positive regulation of DNA binding | 32/7305 | 56/18723 | 4.49e-03 | 1.81e-02 | 32 |
GO:009890115 | Oral cavity | OSCC | regulation of cardiac muscle cell action potential | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
GO:003090116 | Oral cavity | OSCC | midbrain development | 46/7305 | 90/18723 | 1.30e-02 | 4.33e-02 | 46 |
GO:0032770 | Oral cavity | OSCC | positive regulation of monooxygenase activity | 20/7305 | 34/18723 | 1.51e-02 | 4.91e-02 | 20 |
GO:00106447 | Oral cavity | OSCC | cell communication by electrical coupling | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
GO:009015019 | Oral cavity | LP | establishment of protein localization to membrane | 128/4623 | 260/18723 | 7.19e-18 | 1.19e-15 | 128 |
GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
GO:007058519 | Oral cavity | LP | protein localization to mitochondrion | 70/4623 | 125/18723 | 6.73e-14 | 7.02e-12 | 70 |
GO:007265519 | Oral cavity | LP | establishment of protein localization to mitochondrion | 68/4623 | 120/18723 | 6.98e-14 | 7.16e-12 | 68 |
GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
GO:000700617 | Oral cavity | LP | mitochondrial membrane organization | 61/4623 | 116/18723 | 9.44e-11 | 5.63e-09 | 61 |
GO:0051098110 | Oral cavity | LP | regulation of binding | 140/4623 | 363/18723 | 2.47e-09 | 1.10e-07 | 140 |
GO:004477215 | Oral cavity | LP | mitotic cell cycle phase transition | 150/4623 | 424/18723 | 4.38e-07 | 1.23e-05 | 150 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa05031 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0497114 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491519 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541819 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa050311 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALM1 | SNV | Missense_Mutation | | c.400N>A | p.Asp134Asn | p.D134N | P62158 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.574) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | | c.241N>A | p.Asp81Asn | p.D81N | P62158 | protein_coding | deleterious_low_confidence(0.03) | benign(0.043) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
CALM1 | SNV | Missense_Mutation | | c.202G>A | p.Glu68Lys | p.E68K | P62158 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.932) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | | c.202N>A | p.Glu68Lys | p.E68K | P62158 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.932) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | novel | c.169N>A | p.Asp57Asn | p.D57N | P62158 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.972) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | | c.210N>T | p.Leu70Phe | p.L70F | P62158 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.67) | TCGA-05-4415-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
CALM1 | SNV | Missense_Mutation | novel | c.219N>T | p.Met73Ile | p.M73I | P62158 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.654) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CALM1 | SNV | Missense_Mutation | novel | c.17N>T | p.Thr6Ile | p.T6I | P62158 | protein_coding | deleterious_low_confidence(0) | benign(0.272) | TCGA-60-2695-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | novel | c.76N>T | p.Gly26Cys | p.G26C | P62158 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.918) | TCGA-85-8287-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CALM1 | SNV | Missense_Mutation | novel | c.77N>T | p.Gly26Val | p.G26V | P62158 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.983) | TCGA-85-8287-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |